PROPOSED LISTING OF CELL C HOLDINGS LIMITED ON THE MAIN BOARD OF THE JSE LIMITED AND ABRIDGED PRE-LISTING STATEMENT THE ABRIDGED PRE-LISTING STATEMENT DOES NOT CONSTITUTE AN OFFER TO ANY PERSON IN ANY ...

Synthekine Inc., an engineered cytokine therapeutics company, today announced that the company has dosed the first patient in the SYNERGY-101 study. SYNERGY-101 is a global, randomized Phase 2 ...

Net order intake was approximately $19,000,000 and we achieved a positive gross margin of 15%. While this margin result may not represent a new ratable baseline, it demonstrates the progress of our ...

The new NEXO features a comprehensively reengineered powertrain, with a hydrogen fuel cell system that delivers 110 kW of ...

One of the oldest challenges in oncology is creating a drug that kills cancer cells while sparing healthy ones. Peptides are ...

PAVmed Inc.  ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business ...

Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after systemic administration; data also demonstrates that the platform ...

The first new Toyota HiLux in a decade brings plenty to the table on the road and in the showroom. Is it enough?

Good morning, everyone, and welcome, everyone, to the Prelude Therapeutics Investor Conference Call. Today's call is being recorded and is expected to last up to 45 minutes. At this time, I will now ...

Acquired Apeiro Motion (Apeiro), an Israeli robotics innovator developing advanced unmanned ground vehicles (UGVs), quadrupedal robots, and fiber-optic communication spools for radio-independent UAV ...